

## New protocols/documents

- [ID 1996 - Non small cell lung cancer locally advanced or metastatic osimertinib](#)
- [ID 2032 - Non small cell lung cancer metastatic pembrolizumab](#)
- [ID 3512 - Non small cell lung cancer locally advanced durvalumab](#)
- [ID 3510 - Non small cell lung cancer metastatic cARBOplatin, pemetrexed and pembrolizumab](#)
- [ID 3545 - Non small cell lung cancer metastatic ciSplatin, pemetrexed and pembrolizumab](#)
- [ID 3410 - Basal cell carcinoma locally advanced or metastatic sonidegib](#)
- [ID 3555 - Metastatic nivolumab](#)
- [ID 3408 - Non small cell lung cancer locally advanced or metastatic atezolizumab](#)
- [ID 3409 - Non small cell lung cancer locally advanced or metastatic alectinib](#)
- [ID 3253 - Brain metastases \(1-4\) palliative EBRT stereotactic radiosurgery](#)

## Protocols recently updated

- [ID 2035 - Non small cell lung cancer locally advanced or metastatic ceritinib](#)
- [ID 1351 - Non small cell lung cancer locally advanced or metastatic crizotinib](#)
- [ID 380 - Non small cell lung cancer metastatic erlotinib](#)
- [ID 381 - Non small cell lung cancer metastatic gefitinib](#)
- [ID 1600 - Non small cell lung cancer metastatic afatinib](#)
- [ID 230 - Mesothelioma cARBOplatin and pemetrexed](#)
- [ID 1436 - Non small cell lung cancer locally advanced definitive cARBOplatin and PACLitaxel chemoradiation](#)
- [ID 1716 - Small cell lung cancer extensive disease ciSplatin and irinotecan](#)
- [ID 1940 - Colorectal metastatic trifluridine/tipiracil](#)
- [ID 1856 - Non small cell lung cancer advanced or metastatic nivolumab \(now part of ID 3555\)](#)
- [ID 3369 - Breast metastatic palbociclib](#)

## Document updates

- [ID 426](#) - Management of radiation induced nausea and vomiting
- [ID 420](#) - Management of radiation induced oesophageal injury
- [ID 421](#) - Management of radiation induced proctitis
- [ID 1929](#) - Oesophagitis (inflammation of the food pipe)
- [ID 3366](#) - A guide to radiotherapy

## General updates

- Carboplatin AUC  $\geq 4$  classification updated from highly to moderately emetogenic.
- Dexamethasone premedication dose reduced in taxane protocols containing netupitant to take into account the drug interaction between dexamethasone and netupitant.